Several hundred perspectives on the questions facing payers, providers, biopharma, medtech, and digital health — plus our running read on the clinical literature. Start with our sharpest work, or filter to your world.
Phase 1 Licensing Deals Realized Value
By
Sarah Dolman
Biopharma
Read more
Recon authors analyze breast biopsy rates and market dynamics to reveal in an HA Scholar paper how provider environment shapes diagnostic practice
By
Sarah Dolman
In the News
Read more
Preclinical Licensing Deals Realized Value
By
Sarah Dolman
Biopharma
Read more
Artificial Intelligence for Pipeline Discovery and Beyond
By
Sarah Dolman
Biopharma
,
Digital
,
Read more
Beyond drug supply: BIOSECURE and early-stage drug R&D
By
Sarah Dolman
Biopharma
Read more
Multi-Cancer Early Detection tests – Will they become part of regular clinical care?
By
Sarah Dolman
Read more
Is the future of US pharma manufacturing domestic?
By
Sarah Dolman
Biopharma
Read more
Can BiTEs take a bite out of CAR-Ts in hematologic cancers?
